Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] Samsung SDI (006400) – Hanwha Investment & Securities | Delayed EV Recovery · ESS Highlights as Sole Driver · Target Price Cut / 2026-01-07 Research
  • [Research] Samsung Electro-Mechanics (009150) – IBK Securities | MLCC Price Hike · Supply Shortage · Earnings Acceleration / 2026-07-31 Research
  • [IR] SK hynix (000660 / SKHY) – Q3 2024 Earnings Presentation / 2024-10-24 IR Room
  • [Research] Samsung SDI (006400) – Mirae Asset Securities | Data Center ESS · Potential SDC Monetization · Operating Profit Turnaround / 2026-06-26 Research
  • [Research] ABL Bio (298380) – Kyobo Securities | ABL001 Clinical Data · Market Overreaction · Grabody-B Potential / 2026-04-29 Research
  • [Research] Alteogen (196170) – Daishin Securities | Keytruda Qlex Commercial Milestones · RNA Modality Expansion · Platform Re-rating / 2026-08-10 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | DRAM Supply-Demand · AI Infrastructure Finance · Valuation Re-rating / 2026-08-14 Research
  • [Research] SK hynix (000660 / SKHY) – Shinhan | Memory Pricing · LTA · Supplier Pricing Power / 2026-04-06 Research

[Research] SK hynix (000660 / SKHY) – Daishin | Supply Discipline · LTA · Shareholder Returns / 2026-07-30

Posted on July 30, 2026August 24, 2026 By ksb220805@gmail.com

Market: KOSPI (000660)

Brokerage : Daishin Securities

Analyst : Hyeongkeun Ryu

Investment Rating : BUY (Maintain)

Target Price : KRW 3,200,000 (Lowered, applying Target P/B 4.3x)

Core Momentum : Constrained DRAM production growth is expected to enforce supply discipline and sustain earnings expansion through 2027, while multi-year LTAs strengthen long-term customer partnerships and rising FCF supports expanded shareholder returns.

📊 1. [Valuation & Key Financial Metrics]

  • Stock Performance & Investment Rating
    • Investment Rating: BUY (Maintain)
    • Target Price: KRW 3,200,000 (Lowered, applying Target P/B 4.3x)
    • Current Price (As of 26.07.29): KRW 1,401,000
    • Upside Potential: 128.4%
  • Valuation Multiples
    • Annual P/E (PER) Trend: 2024 6.4x → 2025 11.0x → 2026F 7.1x → 2027F 6.4x
    • Annual P/B (PBR) Trend: 2024 1.7x → 2025 3.9x (8.5x per report table) → 2026F 2.6x → 2027F 1.5x
    • Annual ROE Trend: 2024 31.1% → 2025 44.2% → 2026F 106.1% → 2027F 56.6%
  • Key Financial Forecasts
    • 2023: Revenue KRW 32.77T, Operating Loss KRW 7.73T, Pre-tax Loss KRW 11.66T, Net Loss KRW 9.11T, EPS KRW -12,517
    • 2024: Revenue KRW 66.19T, Operating Profit KRW 23.47T, Pre-tax Profit KRW 23.89T, Net Profit KRW 19.79T, EPS KRW 27,182
    • 2025: Revenue KRW 97.15T, Operating Profit KRW 47.21T, Pre-tax Profit KRW 50.47T, Net Profit KRW 42.92T, EPS KRW 58,955
    • 2026F: Revenue KRW 353.15T, Operating Profit KRW 276.52T, Pre-tax Profit KRW 356.02T, Net Profit KRW 270.42T, EPS KRW 374,191
    • 2027F: Revenue KRW 524.55T, Operating Profit KRW 410.06T, Pre-tax Profit KRW 419.53T, Net Profit KRW 306.21T, EPS KRW 419,183

🚀 2. [Market Opportunities & Business Outlook]

  • Transition to Long-Term Growth Models & Supply Discipline
    • Earnings expansion driven by mandatory supply discipline is projected to persist through at least 2027.
    • The differentiating factor in this cycle is the lowered upper bound of DRAM production; even under the most optimistic scenario at the production stage, global DRAM production growth for 2027 is projected to be limited to the low-to-mid 20% range year-over-year.
    • With both customers and suppliers maintaining below-normal inventory levels, attention is focused on potential shortage expansions around August and September alongside server demand recovery.
  • Strengthening Partnerships via Long-Term Agreements (LTAs)
    • Given the nature of the AI industry where technological standards remain unestablished, multi-year LTAs exceeding 3 years are actively pursued to strengthen long-term partnerships with global clients.
    • This establishes a cooperative structure securing stable allies through a natural “Give and Take” of reasonable HBM pricing for SK Group and stable supply chains for Nvidia.
  • Enhanced Shareholder Return Direction
    • The initial financial target of KRW 100 trillion in net cash has already been exceeded.
    • With considerations to utilize 50% of FCF for shareholder returns and expand ADR weightings via share buybacks, overall shareholder return scales are anticipated to increase significantly.

📝 Editor’s Comment (Perspective & Thesis Verification)

The analyst evaluates that although the target price has been lowered to KRW 3.2 million reflecting valuation gaps (Target P/B 4.3x), the fundamental investment thesis regarding structural growth value and earnings expansion in the AI cycle remains completely intact. This perspective places greater emphasis on lower DRAM production ceilings enforcing supply discipline and the institutionalization of long-term growth models rather than short-term market anxieties.

To verify whether this investment thesis unfolds as expected going forward, it is necessary to track whether 2027 global DRAM production growth remains constrained within the low-to-mid 20% range, whether LTA-driven partnerships translate into earnings stability, and whether concrete shareholder return policies—such as allocating 50% of FCF and increasing ADR portions—are implemented. Such changes can be verified through future quarterly earnings releases, official company IR materials, and regulatory filings.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Semiconductors

Post navigation

Previous Post: [Research] SK hynix (000660 / SKHY) – Shinhan | Ultra-Low Inventory · Supply Shortage · Earnings Rebound / 2026-07-30
Next Post: [Research] SK hynix (000660 / SKHY) – Hana | HBM4 · LTA · Valuation Appeal / 2026-07-30

Related Posts

  • [Research] SK hynix (000660 / SKHY) – Shinhan | Supply Constraints · Memory Pricing · Earnings Growth / 2026-05-21 Research
  • [Research] Samsung Electro-Mechanics (009150) – IBK Securities | CAPEX Surge · Foreign Inflows · Target Price Upgrade / 2026-07-16 Research
  • [Research] LigaChem Biosciences (141080) – iM Securities | Clinical Data · Pipeline Progress · Tech Transfer / 2026-05-21 Research
  • [Research] Alteogen (196170) – Hana Securities | Target Price Adjusted on Royalty Structure & Deal Assumptions · Deal Acceleration Starts in 2026 / 2026-01-22 Research
  • [Research] Hanwha Ocean (042660) – Shinhan | Merchant Profit Level-Up · Special Ship Order Variables · Balanced Portfolio / 2026-07-28 Research
  • [Research] Samsung Biologics (207940) – Daishin Securities | Peptide Market Entry · Global Footprint Expansion · Modality Diversification / 2026-07-21 Research
  • [Research] LIG D&A (079550) – SK Securities | CapEx Expansion · Global Interceptor Shortage · Earnings Quality / 2026-08-10 Research
  • [Research] SK hynix (000660 / SKHY) – Shinhan | Supply Constraints · Memory Pricing · Earnings Growth / 2026-05-21 Research
  • [Research] Samsung SDI (006400) – Mirae Asset Securities | Data Center ESS · Potential SDC Monetization · Operating Profit Turnaround / 2026-06-26 Research
  • [Research] ABL Bio (298380) – Mirae Asset Securities | BBB Shuttle Re-rating · IGF1R Competitiveness · ABL001 Data Readout / 2026-03-26 Research
  • [Research] SK hynix (000660 / SKHY) – Eugene Investment | HBM Demand · AI Accelerator Diversification · Profitability / 2026-01-21 Research
  • [Research] Alteogen (196170) – Shinhan Securities | Keytruda SC Growth Accelerates · Favorable Contract Terms · Early June PGR Catalysts / 2026-05-11 Research
  • [Research] LIG D&A (079550) – Daishin Securities | 2Q26 Review · Backlog Realization · Export Margin Expansion / 2026-08-10 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | Enterprise SSD · NAND Pricing · Profitability / 2026-05-18 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme